AU2001238718A1 - Compositions containing a substituted indolealkanoic acid and an angiotensin converting enzyme inhibitor - Google Patents

Compositions containing a substituted indolealkanoic acid and an angiotensin converting enzyme inhibitor

Info

Publication number
AU2001238718A1
AU2001238718A1 AU2001238718A AU3871801A AU2001238718A1 AU 2001238718 A1 AU2001238718 A1 AU 2001238718A1 AU 2001238718 A AU2001238718 A AU 2001238718A AU 3871801 A AU3871801 A AU 3871801A AU 2001238718 A1 AU2001238718 A1 AU 2001238718A1
Authority
AU
Australia
Prior art keywords
compositions containing
converting enzyme
enzyme inhibitor
angiotensin converting
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001238718A
Inventor
Janet Sredy
Michael Van Zandt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institute for Pharmaceutical Discovery Inc
Original Assignee
Institute for Pharmaceutical Discovery Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institute for Pharmaceutical Discovery Inc filed Critical Institute for Pharmaceutical Discovery Inc
Publication of AU2001238718A1 publication Critical patent/AU2001238718A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2001238718A 2000-03-02 2001-02-28 Compositions containing a substituted indolealkanoic acid and an angiotensin converting enzyme inhibitor Abandoned AU2001238718A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US18651100P 2000-03-02 2000-03-02
US60186511 2000-03-02
US19572500P 2000-04-07 2000-04-07
US60195725 2000-04-07
PCT/US2001/006429 WO2001064205A2 (en) 2000-03-02 2001-02-28 Compositions containing a substituted indolealkanoic acid and an angiotensin converting enzyme inhibitor

Publications (1)

Publication Number Publication Date
AU2001238718A1 true AU2001238718A1 (en) 2001-09-12

Family

ID=26882157

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001238718A Abandoned AU2001238718A1 (en) 2000-03-02 2001-02-28 Compositions containing a substituted indolealkanoic acid and an angiotensin converting enzyme inhibitor

Country Status (3)

Country Link
US (2) US6521659B2 (en)
AU (1) AU2001238718A1 (en)
WO (1) WO2001064205A2 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE269861T1 (en) * 1998-03-31 2004-07-15 Inst For Pharm Discovery Inc SUBSTITUTED INDOLALKANIC ACID
TNSN99224A1 (en) * 1998-12-01 2005-11-10 Inst For Pharm Discovery Inc METHODS OF REDUCING GLUCOSE AND TRIGLYCERIDE LEVELS IN SERUM AND FOR ANTIGENESIS SUPPRESSION USING INDOLEALKANOIC ACIDS
US6521659B2 (en) * 2000-03-02 2003-02-18 Institute For Pharmaceutical Discovery, Llc Compositions containing a substituted indolealkanoic acid and an angiotensin converting enzyme inhibitor
CN1684685A (en) * 2002-07-26 2005-10-19 药物研发有限责任公司 Substituted indolealkanoic acids derivative and formulations containing same for use in treatment of diabetic complications
PT1670444E (en) 2003-10-03 2011-07-29 Veijlen N V Use of indoleacetic acid derivatives which increase the serum igf-1 level for the preparation of a therapeutical composition for treatment of various diseases
JP4762902B2 (en) 2003-10-03 2011-08-31 フェーイレン・ナムローゼ・フェンノートシャップ Animal feed composition
GB0324763D0 (en) * 2003-10-23 2003-11-26 Oxagen Ltd Use of compounds in therapy
JP4880591B2 (en) 2004-06-04 2012-02-22 テバ ファーマシューティカル インダストリーズ リミティド Pharmaceutical composition comprising irbesartan
EP1714675A1 (en) * 2005-04-21 2006-10-25 Desol BV Method for increasing the speed of wound healing of injured animals
EP1714674A1 (en) 2005-04-21 2006-10-25 Desol BV Method for improving the fertility of animals
KR20090042808A (en) 2006-07-22 2009-04-30 옥사겐 리미티드 Compounds having crth2 antagonist activity
US7750027B2 (en) * 2008-01-18 2010-07-06 Oxagen Limited Compounds having CRTH2 antagonist activity
CN101932571B (en) 2008-01-18 2014-04-23 奥克萨根有限公司 Compounds having CRTH2 antagonist activity
EP2265581A1 (en) 2008-01-22 2010-12-29 Oxagen Limited Compounds having crth2 antagonist activity
EP2240444A1 (en) 2008-01-22 2010-10-20 Oxagen Limited Compounds having crth2 antagonist activity
GB201322273D0 (en) 2013-12-17 2014-01-29 Atopix Therapeutics Ltd Process
GB201407820D0 (en) 2014-05-02 2014-06-18 Atopix Therapeutics Ltd Polymorphic form
GB201407807D0 (en) 2014-05-02 2014-06-18 Atopix Therapeutics Ltd Polymorphic form
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5238924A (en) * 1984-05-03 1993-08-24 Merck & Co., Inc. Treatment of renal diseases with ace inhibitors
GB9714274D0 (en) * 1997-07-08 1997-09-10 Zeneca Ltd Pharmaceutical composition
CA2233748A1 (en) * 1998-03-31 1999-09-30 Zeneca Limited Medicine
ATE269861T1 (en) * 1998-03-31 2004-07-15 Inst For Pharm Discovery Inc SUBSTITUTED INDOLALKANIC ACID
TNSN99224A1 (en) * 1998-12-01 2005-11-10 Inst For Pharm Discovery Inc METHODS OF REDUCING GLUCOSE AND TRIGLYCERIDE LEVELS IN SERUM AND FOR ANTIGENESIS SUPPRESSION USING INDOLEALKANOIC ACIDS
US6521659B2 (en) * 2000-03-02 2003-02-18 Institute For Pharmaceutical Discovery, Llc Compositions containing a substituted indolealkanoic acid and an angiotensin converting enzyme inhibitor

Also Published As

Publication number Publication date
US20030171405A1 (en) 2003-09-11
WO2001064205A2 (en) 2001-09-07
US20010041722A1 (en) 2001-11-15
WO2001064205A3 (en) 2002-04-25
US6521659B2 (en) 2003-02-18

Similar Documents

Publication Publication Date Title
AU2001238718A1 (en) Compositions containing a substituted indolealkanoic acid and an angiotensin converting enzyme inhibitor
AU2001258771A1 (en) -secretase inhibitors
AU2002219555A1 (en) VLA-4 Inhibitors
AU2002243328A1 (en) Modified rubber-based adhesives
AU2001279202A1 (en) Compositions containing phosphate and xanthan gum variants
AU2002211663A1 (en) Nf-$g(k)b inhibitors
AU1530001A (en) Inhibitor compositions
AU2001247589A1 (en) Non-amidine containing protease inhibitors
AU2001294557A1 (en) Thrombin inhibitors
AU2001245764A1 (en) Novel compounds and compositions as protease inhibitors
AU2001236052A1 (en) Urease inhibitors
AU4433700A (en) Prolyl endopeptidase inhibitor
AU2001270200A1 (en) Fatty acid synthase inhibitors
AUPP982399A0 (en) Mmp inhibitor
AU2001255090A1 (en) Cdk inhibitors having 3-hydroxychromen-4-one structure
AU7961300A (en) Kainic acid neurocytotoxicity inhibitors
AU2001281059A1 (en) Fatty acid synthase inhibitors
AU2003217916A1 (en) Stable formulations of angiotensin converting enzyme (ace) inhibitors
AU1202601A (en) All-organic corrosion inhibitor composition and uses thereof
AU7125700A (en) Enzyme inhibitors
AU2002224550A1 (en) Corrosion inhibitors
AU2001271531A1 (en) Fatty acid synthase inhibitors
AU2002360673A1 (en) Gp41 inhibitor
EP1352911A4 (en) Angiotensin converting enzyme inhibitors
AU2001295966A1 (en) Cell damage inhibitor